Browsing by Author Kannourakis, G

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
Issue DateTitleAuthor(s)Citation
2015EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma.Espinoza, David; Hudson, Amanda; Long, Anne; Martin, Andrew; Pavlakis, Nick; Stockler, Martin; Thompson, John; Yip, Sonia; Azad, A; Davis, I D; Goldstein, David; Harrision, M; Harvie, R; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Lowenthal, Raymond M.; Nelson, C C; Shapiro, J; Steer, C; NH&MRC Clinical Trials Centre; Northern Clinical School: Kolling Institute; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; Central Clinical School: Surgery; NH&MRC Clinical Trials CentreEVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma., Annals of Oncology, vol.26, 6, 2015,pp 1118-1123
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2018Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinomaGibbs, Emma; Martin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Gill, Sanjeev; Goldstein, David; Jain, Vikram; Kannourakis, G; Kim, Jin Won; Kim, Yeul Hong; Liu, Geoffrey; Price, Timothy; Shannon, Jenny; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreHealth-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma, Gastric Cancer, vol.21, 3, 2018,pp 473-480
2014Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)Boyle, Frances; Gebski, Val; Wilcken, Nicholas; Abdi, E; Bull, J; Chirgwin, Jacquie H; et al, Various; Francis, P A; Kannourakis, G; Leong, E; McCarthy, Nicole; Simpson, A; Veillard, Anne-Sophie; Zannino, D; Zdenkowski, Nicholas; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead)Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem), The Breast, vol.23, 2, 2014,pp 142-151
2016Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trialCoates, Alan; Davies, Lucy; Gebski, Val; Bayliss, E; Boyle, F M; Della-Fiorentina, S; et al, Various; Forbes, John F.; Gill, P Grantley; Kannourakis, G; Kling, N; Saunders, Christobel; Zdenkowski, Nicholas; School of Public Health: Public Health; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreObservation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial, Annals of Oncology, vol.27, 5, 2016,pp 806-812